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Background: Retransplantation is the only form of treatment for patients with irreversible graft failure.
The aim of this study was to analyse a single centre's experience of the indications for and outcomes of
retransplantation.
Methods: A total of 196 patients who underwent liver retransplantation using 225 grafts, between
January 1982 and July 2007, were included in the study. The following parameters were analysed: patient
demographics; primary diagnosis; distribution of retransplantation over different time periods; indications
for retransplantation; time interval to retransplantation, and overall patient and graft survival.
Results: Of the 2437 primary orthotopic liver transplantations, 196 patients (8%) required a first regraft,
23 patients (1%) a second regraft and six patients (0.25%) a third regraft. Autoimmune hepatitis was the
most common primary diagnosis for which retransplantation was required (12.7% of primary transplan-
tations). The retransplantation rate declined from 12% at the beginning of our programme to 7.6% at the
end of the study period. The most common indication for retransplantation was hepatic artery thrombosis
(31.6%). Nearly two-thirds of the retransplantations were performed within 6 months of the primary
transplantation. The 1-, 3-, 5- and 10-year patient survival rates following first retransplantation were
66%, 61%, 57% and 47%, respectively. Five-year survival after second retransplantation was 40%.
None of the patients have yet survived 3 years after a third regraft. Donor age of 55 years and a MELD
(Model for End-stage Liver Disease) score of 23 were associated with better outcome following
retransplantation.
Conclusions: First retransplantation was associated with good longterm survival. There was no survival
benefit following second and third retransplantations. A MELD score of 23 and donor age of 55 years
correlated with better outcome following retransplantation.
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Introduction
Orthotopic liver transplantation is currently the life-saving thera-
peutic modality for patients with end-stage liver failure, with 5-
and 10-year survival rates of over 70% and 65%, respectively.1
However, a significant proportion of patients (10.0–19.4%) suffer
graft loss following primary liver transplantation.1–4 Retransplan-
tation is the only viable treatment option for patients with irre-
versible graft failure. The incidence of retransplantation varies
between 5% and 22% worldwide.5–7
Retransplantation presents a clinical dilemma because it is asso-
ciated not only with ethical and economic issues, but also with a
significantly poorer outcome compared with that following
primary transplantation.8–11 Every liver allocated for retransplan-
tation in one patient results in a missed opportunity for primary
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transplantation in another. This assumes greater significance in
the context of increasing donor organ shortage.
However, as the number of transplantations performed every
year using marginal grafts and grafts from non-heart-beating
donors is rising, the incidence of graft loss is likely to increase
proportionately, thereby increasing the need for retransplantation
in the future. Although several studies on retransplantation have
been published in the literature, most reports are based on small
sample sizes.6,12–14 Moreover, only limited data are available on
multiple retransplants and retransplantation experiences from the
UK.11 As our institution is one of the largest transplant centres in
the UK, we reviewed our experience to identify the indications for
retransplantation and evaluate its outcomes.
Materials and methods
This is a retrospective study performed over a 25-year period from
January 1982 to July 2007. All adult patients who underwent
primary cadaveric orthotopic liver transplantation during the
study period at the University Hospitals of Birmingham National
Health Service (NHS) Foundation Trust (UHB) were analysed to
identify those who had subsequent retransplantation.All consecu-
tive patients who had first, second and third retransplants were
included in the study. The data were collected from the prospec-
tively maintained dedicated liver unit database at UHB.
Surgical technique
A standard subcostal approach was used. During the initial part of
the programme, all patients underwent caval replacement with
end-to-end suprahepatic and infrahepatic caval anastomosis.
Temporary veno–venous bypass was introduced in 1987. In recent
years we have increasingly used the piggyback technique with
side-to-side cavo–cavoplasty between the donor and recipient
retro-hepatic inferior vena cava without bypass. In these cases, a
temporary end-to-side porto–caval shunt was performed except
in patients with significantly spontaneous shunts. Following
completion of caval and portal anastomoses, the graft was flushed
with 1 l of 5% dextrose to prevent reperfusion injury, although a
blood flush was used by one surgeon. The hepatic artery was
reconstructed using an end-to-end anastomosis or a jump artery
graft to the aorta or its major branches. Biliary reconstruction
involved either a choledocho-choledochostomy or a Roux-en-Y
choledocho-jejunostomy.
Immunosuppression
A standard triple therapy with prednisolone, azathioprine and
tacrolimus has been used since 2000. Prior to this period, immu-
nosuppression was based on cyclosporin. Tacrolimus trough level
was maintained around 10 ng/ml.Mycophenolate mofetil (MMF)
was used instead of azathioprine in the presence of tacrolimus
toxicity in order to reduce the dose of tacrolimus. In the presence
of MMF, trough tacrolimus level was maintained around 5 ng/ml.
Data analysis
We analysed a number of variables pertaining to the retrans-
planted patients, including: demographic data; primary diagnosis;
time period of retransplantation; indications for retransplanta-
tion; time interval between primary transplantation and retrans-
plantation; preoperative MELD (Model for End-stage Liver
Disease) score; cold ischaemia time, and donor age. The overall
30-day, 90-day, 1-, 3-, 5- and 10-year graft and patient survival
rates were calculated and compared among patients who received
first, second and third retransplantations. Different parameters
predicting survival following retransplantation were also
analysed.
In order to study the effect of increasing experience in trans-
plantation and improvements in perioperative care and immuno-
suppression, the study period was divided into four eras:
1982–1988, 1989–1994, 1995–2001 and 2002–2007. Similarly, pro-
cedures were classified as early and late retransplantations accord-
ing to the time interval between primary transplantation and
retransplantation. Early retransplantations included regrafts per-
formed within 7 days of primary transplantation. Patients were
classified as belonging to one of two groups according to whether
their MELD score was 23 or >23 as 23 was the median MELD
score in the study group. They were also divided into groups
according to length of cold ischaemia time (12 hours and >12
hours) and donor age (55 years and >55 years).
Statistical analysis
Survival data are displayed in the form of Kaplan–Meier curves. A
log-rank test was used to compare survivals. Multivariate logistic
regression analysis was also performed, in which a P-value of
<0.05 was considered statistically significant. spss for Windows
Version 15 (SPSS, Inc., Chicago, IL, USA) was used for data
analysis.
Results
A total of 2437 primary cadaveric orthotopic liver transplanta-
tions were performed during the study period. Of these patients,
196 underwent retransplantation, requiring 225 liver grafts
(9.2%). Out of the 196 patients who underwent a first regraft, 23
patients subsequently underwent a second regraft (0.9%). Six of
the 23 patients who underwent a third liver graft (second regraft)
subsequently required a fourth graft (0.25%). The mean age at the
time of first regraft was 43 years (range 16–68 years).
The primary diagnoses of end-stage liver failure in the 196
retransplanted patients were autoimmune hepatitis (12.7% of
primary transplantations), fulminant hepatic failure (10.7%),
primary sclerosing cholangitis (10.1%), primary biliary cirrhosis
(8.5%), hepatitis C cirrhosis (7.0%), alcoholic liver disease (5.1%)
and others (5.5%). Other aetiologies include cryptogenic cirrho-
sis, tumours of the liver, alpha-1 antitrypsin deficiency and poly-
cystic liver disease (Table 1).
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When the incidence of retransplantation was analysed in the
four different time periods, we found that despite a steady increase
in the number of primary transplantations, the number of
retransplantations had remained relatively unchanged. During
1982–1988, 23 first retransplantations were performed compared
with 191 primary transplantations (12.0%); in 1989–1994, 54 first
regrafts were performed in a primary transplant group of 635
patients (8.5%). In the 1995–2001 period, 61 regrafts were under-
taken in 846 primary transplant patients (7.2%); during 2002–
2007, 58 retransplants were carried out in 765 primary transplant
patients (7.6%). This implies a steady decline in the retransplan-
tation rate from 12.0% at the beginning to 7.6% at the end of the
study period. However, some retransplants were performed in a
later era to the era of first transplant, so these proportions may not
reflect the true retransplant rate of those transplanted in each era.
Analysis of the indications for retransplantation revealed that
hepatic artery thrombosis (HAT)was themost common indication
for first, second and third regrafts (31.6%, 34.8% and 33.3%,
respectively) followed by chronic rejection (22.4% of first regrafts)
and recurrent disease (13.2% of first regrafts). Acute rejection and
primary non-function (PNF) as the cause of primary graft failure
requiring retransplantation were relatively uncommon, account-
ing for only 2.5% and 10.7%, respectively (Table 2).
The median time interval between primary transplantation
and first retransplantation was 69 days (range 1–7870 days. Early
retransplantation was performed in 36 patients (18.4%), the
most common indication being HAT (30.6%). Nearly two-thirds
of the regrafted patients underwent the procedure within
6 months of their primary transplantation. Most of the late
retransplantations were performed within 5 years of primary
transplantation and only 10.7% of patients required retransplan-
tation after 5 years (Table 3). Again, HAT was the predominant
indication for late retransplantation, accounting for 31.3% of
cases.
The median preoperative MELD score of the retransplanted
patients was 22.3 (range 6–40). The median donor age was 36
years (range 9–72 years). The median cold ischaemia time was
597 min (range 131–1151 min).
Survival and prognostic factors
Overall graft and patient survival rates following first retrans-
plantation are shown in Fig. 1. Figure 2 compares the cumulative
survival curves following first, second and third retransplanta-
tions. In essence, 1-, 3-, 5- and 10-year patient survival rates fol-
lowing first retransplantation were 66%, 61%, 57% and 47%,
respectively. After second retransplantation, patient survival
figures fell to 45% at 1 year, 40% at 3 years, 40% at 5 years and
25% at 10 years. Following a third regraft, 24% of patients sur-
vived up to 1 year and none of the patients survived up to 3
years.
Table 1 Primary aetiology of end-stage liver disease in retrans-
planted patients
Primary diagnosis Primary
transplantation,
n
First
retransplantation,
n (%)
Primary biliary cirrhosis 634 54 (8.5)
Primary sclerosing
cholangitis
267 27 (10.1)
Fulminant hepatic failure 327 35 (10.7)
Autoimmune hepatitis 150 19 (12.7)
Alcoholic liver disease 255 13 (5.1)
Hepatitis C cirrhosis 272 19 (7.0)
Others 532 29 (5.5)
Total 2437 196
Table 2 Indications for retransplantation
Indications First retransplantation, n (%) Second retransplantation, n (%) Third retransplantation, n (%)
Acute rejection 4 (2.0) 0 0
Chronic rejection 44 (22.4) 6 (26.1) 1 (16.7)
Graft infarction 26 (13.2) 3 (13.0) 0
Hepatic artery thrombosis 61 (31.1) 8 (34.8) 2 (33.3)
Primary non-function 21 (10.7) 0 1 (16.7)
Recurrent disease 26 (13.2) 4 (17.4) 2 (33.3)
Others 14 (7.1) 2 (8.7) 0
Total 196 23 6
Table 3 Time interval between primary transplantation and first
retransplantation
Time interval First
retransplantation,
n (%)
0–7 days 36 (18.4)
8–30 days 38 (19.4)
1–6 months 51 (26.0)
6 months–1 year 8 (4.1)
1–3 years 33 (16.8)
3–5 years 9 (4.6)
5–10 years 11 (5.6)
>10 years 10 (5.1)
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Univariate analysis was performed initially to identify factors
predicting survival (Table 4A). There was a statistically significant
difference in survival in different eras of operation. Patients who
underwent retransplantation during 2002–2007 had better
survival than those who underwent earlier procedures (P = 0.006)
(Fig. 3). Early retransplantation was associated with worse
outcome compared with late retransplantation (P = 0.015)
(Fig. 4). Patients who had retransplantation for PNF and graft
300.00250.00200.00150.00100.0050.000.00
Time 1
1.0
0.8
0.6
0.4
0.2
0.0
C
u
m
u
la
ti
ve
 s
u
rv
iv
al
Patient survival-
censored
Graft survival-
censored
Patient survival
Graft survival
Group 1
Numbers at risk: 
Patient survival         196          83             52            31           13 
Graft survival            196          79             46            26           11 
Figure 1 Survival curves showing patient and graft survival rates after first retransplantation
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Figure 2 Cumulative survival curves comparing outcomes after first, second and third retransplantations
220 HPB
HPB 2010, 12, 217–224 © 2010 International Hepato-Pancreato-Biliary Association
infarction had poorer survival in comparison with patients with
other indications (P = 0.028). Other factors, including primary
diagnosis (P = 0.507), MELD score (P = 0.919), cold ischaemia
time (P = 0.406) and donor age (P = 0.428), were not found to be
statistically significant. However, on stepwise logistic regression
analysis, MELD score (P = 0.029) and donor age (P = 0.036)
reached statistical significance, but all the other factors mentioned
above did not (Table 4B, C).
Table 4 (A) Univariate analysis of variables predicting outcome following retransplantation. (B) Multivariate analysis of the variables predicting
outcome following retransplantation. (C) Stepwise logistic regression analysis of variables predicting outcome following retransplantation
Variable Odds ratio 95% CI P-value
(A)
Period of retransplantation
1982–1988 – – –
1989–1994 3.24 1.59–6.58 0.001
1995–2001 1.96 1.04–3.69 0.036
2002–2007 1.68 0.89–3.18 0.108
Early vs. late retransplantation
0–7 days – – –
8–30 days 1.93 1.19–3.14 0.008
>30 days 1.00 0.59–1.69 0.998
Indications for retransplantation
Acute rejection – – –
Hepatic artery thrombosis 1.41 0.31–6.31 0.653
Primary non-function 0.73 0.26–2.12 0.570
Graft infarction 1.53 0.49–4.70 0.459
Recurrent disease 1.84 0.62–5.45 0.271
Chronic rejection 1.09 0.36–3.30 0.885
Biliary complications 0.71 0.24–2.09 0.538
Others 0.72 0.16–3.24 0.672
Primary diagnosis
Alcoholic cirrhosis – – –
Autoimmune hepatitis 1.56 0.66–3.69 0.309
Acute liver failure 1.39 0.65–2.97 0.397
Hepatitis C cirrhosis 0.67 0.31–1.43 0.300
Primary biliary cirrhosis 1.24 0.54–2.84 0.606
Primary sclerosing cholangitis 1.05 0.57–1.96 0.868
Others 1.02 0.49–2.09 0.951
Preoperative MELD score
23 – – –
>23 0.98 0.63–1.51 0.921
Cold ischaemia time
>12 hours – – –
12 hours 0.84 0.55–1.28 0.419
Donor age
>55 years – – –
55 years 0.72 0.31–1.66 0.445
Variable Odds ratio 95% CI P-value
(B)
Period of retransplantation
1982–1988 – – –
1989–1994 5.93 2.47–14.19 0.000
1995–2001 3.21 1.52–6.80 0.002
2002–2007 2.43 1.21–4.87 0.012
Early vs. late retransplantation
0–7 days – – –
8–30 days 0.92 0.35–2.41 0.881
>30 days 0.50 0.23–1.07 0.075
Indications for retransplantation
Acute rejection – – –
Hepatic artery thrombosis 1.50 0.26–8.65 0.645
Primary non-function 0.57 0.18–1.81 0.343
Graft infarction 0.94 0.20–4.32 0.937
Recurrent disease 1.52 0.41–5.63 0.530
Chronic rejection 0.85 0.26–2.75 0.787
Biliary complications 0.33 0.10–1.08 0.068
Others 0.28 0.05–1.44 0.130
Primary diagnosis
Alcoholic cirrhosis – – –
Autoimmune hepatitis 1.72 0.69–4.30 0.239
Acute liver failure 1.40 0.59–3.29 0.440
Hepatitis C cirrhosis 0.45 0.20–1.04 0.063
Primary biliary cirrhosis 1.26 0.51–3.10 0.606
Primary sclerosing cholangitis 0.81 0.42–1.59 0.557
Others 0.84 0.39–1.82 0.670
Preoperative MELD score
23 – – –
>23 0.93 0.54–1.62 0.821
Cold ischaemia time
>12 hours – – –
12 hours 0.61 0.38–0.98 0.042
Donor age
>55 years – – –
55 years 1.13 0.47–2.74 0.775
(C)
Preoperative MELD score 23 1.03 1.00–1.06 0.029
Donor age 55 years 1.02 1.00–1.04 0.036
95% CI, 95% confidence interval; MELD, Model for End-stage Liver Disease
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Discussion
This study confirms that liver retransplantation is an effective
treatment modality for patients with primary graft failure and
offers good longterm survival.
The incidence of retransplantation in our study was 9.2%. This
is comparable with the figures quoted in the literature, which vary
between 5% and 22%.5–7,14–15 At our centre, the retransplantation
rate fell from 12.0% at the beginning of our study period to 7.6%
at the end of it, despite a steady increase in both the number of
primary transplantations and the use of marginal grafts. This
reflects improvements in intraoperative monitoring, surgical
technique, organ preservation, postoperative care and effective
immunosuppressive therapy.
The most common indication for retransplantation in this
study was HAT, accounting for around one-third of all patients
undergoing first, second or third retransplantations. Published
data show that HAT accounted for 11.5–36.0% of all retransplant
cases in adults.1–4,16,17 Although technical reasons commonly
account for HAT, it is also known to be associated with older
donors andmarginal donors.18,19 The higher rate of HAT requiring
retransplantation in our study possibly reflects our policy to
retransplant all HAT patients as we feel that any other interven-
tional procedure may delay the decision for retransplantation and
worsen the patient’s prognosis. We did not find any association
between the use of arterial conduit and the development of HAT.
Nishida et al. found that protocol Doppler ultrasonography of the
liver graft detects early HAT and that urgent revascularization
based on this could significantly reduce the incidence of graft loss
requiring retransplantation in the paediatric population.20
The proportion of regrafts performed for PNF was lower in our
study (10.7% of patients) compared with the published data. The
incidence of PNF varies from 10.0% to 32.3% worldwide.1–4,16,17
Jain et al. demonstrated that PNF was the most common indica-
tion for retransplantation, accounting for 32.3% of cases.2 The
lower incidence of PNF in our centre may be attributable to strict
graft selection, harvesting and graft preservation protocols.
The overall 1-, 3-, 5- and 10-year survival rates following first
retransplantation were 66%, 61%, 57% and 47%, respectively.
These are comparable with rates cited in the literature.8,15,21 These
survival figures are lower than equivalent rates after primary
transplantation. Despite its inferior results compared with
primary grafting, hepatic retransplantation cannot be abandoned
because it is the only treatment option for patients with a failing
liver graft. Hence a rationalized approach is needed to balance the
fulfilling of responsibilities to patients requiring retransplantation
and to patients awaiting a primary liver graft. This might be
achieved by identifying a subgroup of patients who are likely to
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Figure 3 Cumulative survival curves comparing the four different eras of retransplantation
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have a poor outcome following retransplantation. In the present
study, 1-year patient survival was 45% after second retransplan-
tations and 24% after third retransplantations. Based on these
outcomes, if the general rule requiring a 50% survival rate at 5
years were adhered to, no patients should undergo second or third
retransplantations. Similar findings have been reported from
Pittsburg and Los Angeles.11,22
Analysis of the prognostic factors using the logistic regression
model revealed preoperative MELD score and donor age as inde-
pendent risk factors predicting outcome following regrafts.
Several authors have attempted to devise risk scores and predict
survival after retransplantation.1,11,19,21,23–25 A number of factors
have been found to significantly affect outcome after retransplan-
tation. These include donor variables (age and gender), recipient
variables (bilirubin, creatinine, recipient age, preoperative
mechanical ventilation and choice of immunosuppression),11,22
MELD score,25,26 timing of retransplantation,6,9,27 use of intraop-
erative blood products10 and indications for retransplantation.8
The timing of retransplantation has been shown to play a sig-
nificant role in both patient and graft survival.8,27 Chen et al. dem-
onstrated that patients in whom the interval to retransplantation
was 8–30 days displayed lower survival rates compared with those
who underwent later retransplantations.6 They reasoned that this
might be a consequence of postoperative sepsis and more severely
compromised clinical status because of the delay in retransplan-
tation, thereby leading to higher post-transplant mortality. In the
current study, early retransplantation within 7 days of primary
grafting was found to be a predictor of poorer outcome on
univariate analysis. However, this did not reach statistical signifi-
cance on multivariate regression analysis. The higher incidence of
mortality following early retransplantation may be explained by
the fact that the initial period after transplantation represents that
of the most intense immunosuppression. This is supported by
another study which found that the most common cause of death
in this group of patients was sepsis.11 Moreover, patients who need
early retransplantation are by definition suffering from acute liver
failure, whereas those who require late retransplantation usually
have chronic liver failure, which accounts for the higher mortality
in the former group.
The indication for retransplantation has not been confirmed as
a predictor of prognosis in most studies.10,11,15 Facciuto et al.
showed that patients who underwent retransplantation for recur-
rent hepatitis C had poorer 90-day survival than those who
underwent retransplantation for other indications, although this
difference was not statistically significant.10We found that patients
with PNF and graft infarction had a significantly poorer outcome
on univariate analysis. However, this did not reach significance on
multivariate analysis. This is possibly because this group of
patients would have been clinically septic and immunocompro-
mised prior to second grafting.
> 30 days
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The MELD scale was implemented in 2002 to evaluate the
severity of disease in patients with end-stage liver disease and to
stratify patients for prioritization for transplantation. It has been
shown to be a good predictor of pre-transplant mortality,
although it is a poor indicator of the outcome of the transplanta-
tion itself.26 Contrary to this, Rosen et al. found MELD scores to
be predictive of survival following retransplantation when they
stratified disease severity usingMELD cut-off scores of <22, 22–31
and 32.25 This was confirmed in our study, in which a MELD
cut-off score of 23 was used.
This study demonstrated that a MELD score of 23 and donor
age of 55 years correlated with a better outcome following
retransplantation. We conclude from our data that first retrans-
plantation is associated with good longterm graft and patient
survival. However, candidates for second and third retransplanta-
tions should be scrutinized carefully and the procedure consid-
ered only in a selected group of low-risk patients. Second and
third retransplantations should not be performed routinely in all
patients with failing second grafts because there is no demon-
strable longterm survival benefit.
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